8-K: BillionToOne Reports Strong Q1 2026 Results, Raises Guidance

BillionToOne announced robust first quarter 2026 financial results, with an 84% revenue increase and a significant rise in gross profit margin, leading to raised full-year revenue guidance.

Summary

• BillionToOne reported total revenue of $108.4 million for the first quarter of 2026, an 84% increase from $59.0 million in Q1 2025.
• Prenatal clinical testing revenue grew 72% to $96.5 million, while oncology clinical testing revenue surged 392% to $10.7 million.
• Gross profit margin improved to 73% from 64% in the prior year's quarter.
• The company delivered 188,000 tests, a 44% increase year-over-year.
• Income from operations was $17.8 million, a significant turnaround from a $2.3 million operating loss in Q1 2025.
• Net income for the quarter was $18.0 million, or $0.34 per diluted share, compared to a net loss of $4.0 million in Q1 2025.
• Full-year 2026 revenue guidance has been raised to a range of $450 million to $465 million, representing 48% to 52% growth over 2025.
• The company launched Unity ConfirmTM, a non-invasive confirmation assay for high-risk prenatal screening results.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a very positive filing due to exceptional revenue growth, significant margin expansion, a return to profitability, and raised forward-looking guidance, indicating strong market traction and operational execution.

Positives

• Total revenue increased by 84% year-over-year to $108.4 million.
• Prenatal testing revenue grew by 72% to $96.5 million.
• Oncology testing revenue saw substantial growth of 392% to $10.7 million.
• Gross profit margin improved by 9 percentage points to 73%.
• Test volume increased by 44% to 188,000 tests delivered.
• The company achieved income from operations of $17.8 million, a reversal from a loss.
• Net income was $18.0 million, a significant improvement from a net loss in the prior year.
• Full-year 2026 revenue guidance was raised to $450 million - $465 million.

Negatives

• Operating expenses increased by 52% to $61.3 million compared to the prior year's quarter.
• While profitable, the company expects to continue significant investments, aiming to maintain profitability near current levels.

Risks

• Forward-looking statements are subject to risks and uncertainties, including those discussed in the company's SEC filings.
• Actual outcomes and results could differ materially from forward-looking statements due to factors beyond the company's control.
• The company's ability to continue generating profitability may be impacted by significant continued investments.

Future Outlook

BillionToOne has raised its full-year 2026 revenue guidance to a range of $450 million to $465 million, representing 48% to 52% growth over 2025. The company expects to continue generating profitability approaching current levels, even with significant ongoing investments.

Management Comments

• "Our first quarter performance underscores the continued momentum we are building through our differentiated technology platform, category-defining products, and disciplined execution."
• "In Q1 2026 we launched additional prenatal and oncology offerings and significantly expanded our payor contracts, reaching $300 million contracted lives in the U.S."
• "We remain focused on addressing some of healthcares most complex challenges. As we move through 2026, we believe we are only beginning to realize the full potential of our platform."

Industry Context

StockSavvy.ai notes that BillionToOne's strong Q1 2026 performance and raised guidance align with the growing demand for advanced molecular diagnostics, particularly in prenatal and oncology screening, where accuracy and accessibility are key differentiators. The company's focus on non-invasive testing methods like Unity ConfirmTM positions it well within a competitive landscape prioritizing patient safety and improved diagnostic pathways.

Comparison to Industry Standards

• BillionToOne's revenue growth of 84% in Q1 2026 significantly outpaces the typical growth rates seen in the broader molecular diagnostics sector, which often experiences high single-digit to low double-digit annual growth.
• The gross profit margin of 73% is exceptionally strong for a diagnostics company, often indicating efficient operations and strong pricing power, compared to industry averages that can range from 50-65%.
• The company's shift from an operating loss to a significant operating income of $17.8 million in Q1 2026 demonstrates a rapid scaling and operational leverage that is not commonly achieved so quickly in the industry.
• The raised full-year revenue guidance of 48%-52% growth for 2026 suggests a market adoption and expansion rate that is considerably higher than many established players in the diagnostics space.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, and raised future guidance, likely leading to increased shareholder value.
• Employees: Positive impact from company growth and success, potentially leading to increased opportunities and job security.
• Customers: Benefit from advanced and accessible diagnostic tests, including the new Unity ConfirmTM assay for safer prenatal screening.
• Payors: Increased contracted lives ($300 million) indicate broader adoption and integration into healthcare networks.

Next Steps

• Continue to expand payor contracts.
• Focus on addressing complex healthcare challenges with their platform.
• Realize the full potential of their technology platform throughout 2026.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with significant year-over-year growth in revenue and profitability, coupled with a substantial improvement in gross margins. The raised full-year guidance indicates strong execution and market demand. The launch of innovative products like Unity ConfirmTM further solidifies its competitive position. These factors collectively suggest a compelling investment opportunity with significant upside potential.

Keywords

BillionToOne, Molecular Diagnostics, Prenatal Testing, Oncology Testing, Q1 2026 Results, Revenue Guidance, Unity Confirm, NASDAQ:BLLN